Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
mikeelogan

Common Asthma Steroids Linked To Side Effects In Adrenal Glands | Fox News

San Francisco Salt Company Teams Up With the National Psoriasis Foundation for... -- SAN FRANCISCO, April 22, 2015 /PRNewswire/ --

Corticosteroids are man-made drugs designed to mimic the hormone cortisol, which the adrenal glands produce naturally. The drugs are usually used to counter inflammation in a wide range of conditions, including asthma, psoriasis, rheumatoid arthritis, lupus, blood cancers and organ transplants. People with adrenal insufficiency do not make enough of two hormones, cortisol and aldosterone. Cortisol helps the body respond to stress, recover from infections and regulate blood pressure and metabolism.
For the original version including any supplementary images or video, visit http://www.foxnews.com/health/2015/04/24/common-asthma-steroids-linked-to-side-effects-in-adrenal-glands/

Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog - psoriasis on eyelids Yahoo Finance

Fumaderm, acquired by Biogen in 2006, accounted for $62 million of Biogen's $8.2 billion in 2014 product revenue. Biogen changed hands recently at $421.08, down 0.24 percent. In January, Bass, who runs Dallas-based Hayman Capital Management L.P., told an investment conference in Norway of plans to challenge pharmaceutical patents via a so-called Inter Partes Review process created by Congress in 2012. The process entails hearings before a U.S. Patent Office panel as a cheaper and faster alternative to court trials, and was formed to help fight patent trolls.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/kyle-bass-challenges-biogen-fumaderm-165806709.html

Aldosterone helps maintain the right amounts of salt, potassium and water in the body. While on steroids, the body often produces less of these hormones naturally, and after coming off the drugs it can take a while for natural production to ramp back up. The result is adrenal insufficiency, which can be treated with medication to replace cortisol or aldosterone. Dekkers and colleagues analyzed 74 research articles published from 1975 to 2014, covering a total of 3753 study participants, to see how different doses and types of corticosteroid treatment might impact the likelihood of developing adrenal insufficiency after treatment. Researchers found the risk of adrenal insufficiency was highest when corticosteroids were taken orally or injected, and lower with inhaled, nasal or topical treatment. When they looked just at patients using steroids for asthma, the researchers found that the risk of adrenal insufficiency was about 7 percent with inhaled corticosteroids, but about 44 percent with other formulations including oral inverse psoriasis pictures medication. Only about 2 percent of asthma patients on the lowest dose of steroids experienced adrenal insufficiency, compared with about 22 percent on the highest doses.
For the original version including any supplementary images or video, visit http://news.yahoo.com/common-asthma-steroids-linked-side-effects-adrenal-glands-182107481.html

Common asthma steroids linked to side effects in adrenal glands - Yahoo News

By mostly word of mouth, the demand for Dead Sea Salt from those suffering from psoriasis has organically taken off and amazed us. I'm personally touched every time we receive a testimonial from a customer stating that our Dead Sea Salt has made a big improvement in managing their psoriasis," says Lee Williamson, owner of San Francisco Salt Company. More Than Skin Deep is being held on Saturday, April 25th in San Mateo at the Hilton Garden Inn. This event is a free educational lecture being held by Dermatologist Dr. Koo.
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/san-francisco-salt-company-teams-up-with-the-national-psoriasis-foundation-for-2015-events-300069916.html

Kyle Bass Challenges Biogen Fumaderm Patent - Yahoo Finance

Oncology drugs will be under pricing pressure in 2015 as new immuno-oncology therapies enter the market. Nevertheless, we cautiously watch Novartis' efforts to realign its portfolio in order to focus on its core segments of pharmaceuticals, eye care and generics. We expect investor focus to remain on Cosentyxs progress and launch of LCZ696 upon a potential approval (launch expected from the third quarter). Meanwhile, Novartis has four immune-oncology molecules in its pipeline, which are scheduled to enter clinical stage later in the year including the checkpoint inhibitors PD-1, TIM-3 and LAG-3. Right now, Shire SHPG looks favorably placed in the etiology of psoriasis healthcare sector with a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research?
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/novartis-nvs-beats-earnings-q1-140002995.html

Don't be the product, buy the product!

Schweinderl